To that end, Meersch, Zarbock et al. performed the PrevAKI trial, a single-center randomized controlled trial which identified cardiac surgical patients at high risk of AKI by using urinary TIMP-2 and IGFBP7 (Nephrocheck®) four hours after CPB (Table 5). The gene discussed is TIMP2; the disease is acute kidney injury.